Chordoma Foundation

PI3K/Akt/mTOR

The PI3K/Akt/mTOR Pathway in Chordoma

Understanding the Pathway: Activation of Akt, either by growth factors or by RAS, leads to the phosphorylation of PI3k and PDK-1 and the subsequent inactivation of TSC1/TSC2 complex. When this complex is inactivated, Rheb is able to phosphorylate mTOR. This leads to the downstream phosphorylation of p70S6K and 4E-BP1. PTEN is a tumor suppressor gene whose expression negatively regulates the interactions of this pathway.

Activation of the PI3k/Akt/mTOR signaling pathway suppresses apoptosis, promotes cell growth, and drives cellular proliferation.1 Abnormalities involving the various components of this complicated pathway have been implicated in a number of human cancers.

Attention was first focused on this pathway after numerous reports of chordoma tumors in individuals with tuberous sclerosis syndrome. This disease involves the TSC1 and TSC2 genes, key players in the PI3K/Akt/mTOR pathway. Further investigation revealed that the PI3k/Akt/mTOR pathway is activated in the majority of chordomas and suggested that signaling through PI3k, Akt, and mTOR may be critical to chordoma pathogenesis.2  Cell lines and mouse models treated with substances that inhibit mTOR, PI3K, or Akt not only diminish the pathway’s activity but also reduce chordoma cellular proliferation and even trigger cell death. Though response has been mixed, a number of patients have been treated with drugs that inhibit mTOR have experienced positive results. Researchers continue to evaluate whether this pathway can be targeted to treat chordoma, and this page contains a summary of their published research.

Molecular Evidence


Copy Number Variation

Chromosomal Aberrations:

  • Loss of chromosomal regions harboring genes involved in the pathway have been reported in chordomas. Among the losses are PI3KCA at 3q26, mTOR at 1p36.2, and negative regulator PTEN at 10q23.3 4 5 6 7 8

Gene Copy Number Variation:

  • Gene copy number variations in mTOR, RPS6, and S6 have been reported.6 9 10
  • Copy number variation in TSC1 and TSC2 has not been observed, indicating that something else is responsible for inactivation of the mTOR-inhibiting TSC1/TSC2 complex.9

Germline Genetic Variant

  • In 11 cases of chordoma occurring in individuals with tuberous sclerosis (TSC), one individual was found to have a germline TSC2 mutation and another a germline TSC1 mutation. Biallelic inactivation was confirmed in both and served to inactivate the TSC1/TSC2 complex, abolishing its inhibitory effect on mTOR.11 Clinical features in TSC-associated pediatric chordomas differ from the general pediatric chordoma population.12
  • In a chordoma patient with family history of TSC, a nonsense germline mutation was detected in TSC1 and was shown to cause translation termination.13

Somatic Mutation

  • Somatic mutations are largely absent in mutation hotspots in genes Rheb, PI3KCA, or PTEN, indicating that mutation is not responsible for the abnormal signaling of these components of the pathway.6 9
  • In a 2014 study Choy et al. detected a mutation in PI3KCA in only 1 of 45 chordoma samples tested.14 Similarly, Tauziède-Espariat et al. found 2 mutations (p.H1047L and p.E542K) in the PIK3CA gene in 5% of cases analyzed (3 tumors from 2 patients).15
  • Analysis of 104 chordoma cases found mutations in PIK3CA in 9/104 samples, in PIK3R1 and MTOR in 1/104 samples and in PTEN in 6/104 samples along with a disruptive rearrangement in PTEN in an additional sample.16

Protein Expression and Activation

  • Akt: Total Akt and p-Akt are detected in the majority chordomas analyzed. Lack of mutations in the TSC1 and TSC2 genes, coupled with the presence of the TSC1 and TSC2 proteins and the phosphorylation of TSC2 in nearly all samples, indicate that phosphorylation of TSC2 by Akt, rather than genetic mutation, serves to inactivate the TSC1/TSC2 complex.1 6 9 10 17 18 19 Strong staining for Akt has been observed in a significantly higher fraction of chordoma tissues than fetal nucleus pulposus tissues.20 Kinase analysis of 10 chordoma samples revealed frequent and strong up regulation of the AKT signaling pathway.7 p-AKT expression varies among chordoma cell lines.21 22 Poor survival rate has been directly associated with pAKT positivity.19
  • PI3K: PI3K is detected in nearly all chordomas.6 23
  • mTOR: Total mTOR is present in nearly all chordomas evaluated, and p-mTOR has been detected in more than half.1 6 9 10 18 19 23 24
  • S6/S6K: Chordomas show variable activation of p70S6K or RPS6, though most show expression of the unactivated proteins. Their activation is important for protein synthesis. Hypermethylation of the RPS6 promoter has not been observed, so the absence of activated p70S6K (p-p70S6K) and RPS6 (p-RPS6K) cannot be attributed to lack of RPS6 gene expression.1 6 9 10 15 18 25
  • PDK-1: Key downstream protein PDK-1 is present and phosphorylated in all samples analyzed, providing further evidence that the PI3K pathway is activated.1
  • PTEN: Though present, PTEN chromosomal alterations were not found to alter gene expression.6  Chordomas have shown variable immunoreactivity for the PTEN protein and absence of PTEN may lead to constitutive Akt phosphorylation and activation of the pathway.9 10 23 24 25 26 27 Wu et al. suggest that PTEN expression is associated with degree of bone invasion.23
  • 4E-BP1/eIF-4E: 4E-BP1 has an inhibitory effect on eIF-4E, but the inhibition is released when 4E-BP1 is phosphorylated so that mRNA translation continues. Total 4E-BP1 and p-4E-BP1 are detected in nearly all chordomas tested.6 9 10 15 18 25 Total eIF-4E is also detected, indicating that the protein is free in most chordomas to promote cellular proliferation and protein synthesis.

Pathway Activation

  • Serum-starved U-CH1 cells espress high levels of p-PRAS40, a negative regulator of MTORC1, p-TSC2, and p-AKT, indicating that Akt signaling is constitutively active independent of growth factors.25
  • p-mTOR has been detected in more than half of chordomas analyzed. p-p70S6K is thought to be a better biomarker for activation of the PI3K/Akt/mTOR pathway than p-mTOR, and it has also been detected in more than half of chordomas analyzed.9 10 18 Taking both these phosphorylated proteins into account, Presneau et. al. estimated that the pathway is activated in ~65% of chordomas.9 More recently, Tauziède-Espariat et al. found activation in 46% of of chordoma, based on expression of p4EBP1 and dually phosphorylated pS6 (ser 240/244 and ser 235/236).15
  • Gene loci that were found to be hypermethylated in cancer samples versus controls fell into a number of cancer-related pathways, including the PI3k/Akt/mTOR pathway.28
  • Transcriptome microarray analysis comparing 4 tumors with high brachyury expression versus 4 tumors with low brachyury expression found that the PI3K/AKT signaling pathway is significantly upregulated when brachyury is overexpressed.29

Preclinical Evidence


In-vitro Efficacy

  • Rapamycin: Treatment of chordoma cell lines with the mTOR inhibitor has been shown to have a variety of tumor suppressive effects, including inhibition of cell growth and proliferation, decreased cell number, and reduced phosphorylation of Akt and P70S6K.25 30
  • Wortmannin: Treatment of U-CH1 with the PI3K inhibitor significantly decreased phosphorylation of pathway activator Akt.25 Treatment of U-CH2 with wortmannin suppressed brachyury mRNA expression.29
  • PI-103 (+/-doxorubicin or cisplatin): Treatment of U-CH1 with the dual PI3K/mTOR inhibitor reduced cellular proliferation and increased apoptosis, and the addition of a chemotherapy drug increases the tumor-suppressive effects.1
  • Ly294002: Treatment of U-CH2 with BEZ235 suppressed brachyury mRNA expression. 29
  • BEZ235: Treatment of U-CH2 with BEZ235 suppressed cell growth and decreased brachyury mRNA and protein expression. 29
  • PDGFR Inhibition: PTEN-deficient primary culture cells showed greater resistance to a PDGFR inhibitor than those that were not PTEN-deficient. PTEN restoration in two cell lines decreased proliferation and established sensitivity to the PDGFR inhibitor in both cases.31
  • β-β-dimethylacrylshikonin: Treatment of 4 chordoma cell lines with β-β-dimethylacrylshikonin (DMAS) resulted in decreased Akt, p-Akt, and p-Erk protein expression in the majority of cell lines tested.32

In-vivo Efficacy

  • Rapamycin: Rapamycin treatment reduced tumor volume in mice grafted with tumors derived from chordoma cell line U-CH1.30
  • MLN0128: Treatment of chordoma mouse xenografts with this ATP-competitive dual MTORC1/2 inhibitor decreased activity of the PI3k/Akt/mTOR signaling pathway (p = 0.019).33
  • Rapamycin: Rapamycin delayed the onset of tumor formation in a newly developed zebrafish model of chordoma and improved the survival of tumor-bearing fish.34
  • LY294022: PI3K inhibitor LY294022 had no inhibitory/activating effects on tumor growth in a zebrafish model of chordoma, suggesting that mTOR can be activated by the Ras oncogene rather than by PI3K.34

Clinical Evidence


Case Reports

There have been a number of case reports publishing the results of treating chordoma patients with a therapeutic agent that targets the PI3k/Akt/mTOR signaling pathway.

  • Rapamycin: One patient experienced disease progression after two months treatment (after switching from PDGFR inhibitor Imatinib).35 Another patient with a recurrence experienced 6.1 times slower tumor growth during 10 months of treatment after surgery.30
  • Imatinib + Sirolimus: In a case series of 10 patients with progressive, advanced chordoma, 9 were evaluable for response. By RECIST criteria, 1/9 showed partial response, 7/9 reached stable disease, 1/9  remained progressive after 3 months. Clinical benefit rate was determined to by 89%, with 7 of 9 patients reporting improvement in the symptoms they had prior to treatment.36
  • Everolimus: A patient with sacral chordoma was treated with the PDGFR inhibitor imatinib for 4 months until slight progression occurred and then the mTOR inhibitor everolimus was added and stable disease was achieved for 16 months. After disease progression, the patient was treated with the EGFR inhibitor erlotinib which led to a brief clinical benefit.37
  • Temsirolimus: One patient treated with the mTOR-inhibitor temsirolimus was included in a retrospective review of 80 patients.38

Clinical Trials

  • Imatinib + Everolimus: A phase 2 clinical study (EUDRACT number: 2010-021755-34) of 43 adults with progressive advanced chordoma treated with imatinib plus everolimus found limited antitumor activity. However, a subgroup of patients with highly phosphorylated mTOR effectors were responsive, suggesting that activation of the mTOR pathway could be predictive of response to imatinib plus everolimus.39

References

1.
Schwab J, Antonescu C, Boland P, et al. Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma. Anticancer Res. 2009;29(6):1867-1871. [PubMed]
2.
Williams B, Raper D, Godbout E, et al. Diagnosis and treatment of chordoma. J Natl Compr Canc Netw. 2013;11(6):726-731. [PubMed]
3.
Rinner B, Weinhaeusel A, Lohberger B, et al. Chordoma characterization of significant changes of the DNA methylation pattern. PLoS One. 2013;8(3):e56609. [PubMed]
4.
Scheil S, Brüderlein S, Liehr T, et al. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer. 2001;32(3):203-211. [PubMed]
5.
Hallor K, Staaf J, Jönsson G, et al. Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation. Br J Cancer. 2008;98(2):434-442. [PubMed]
6.
Tamborini E, Virdis E, Negri T, et al. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. Neuro Oncol. 2010;12(8):776-789. [PubMed]
7.
Dewaele B, Maggiani F, Floris G, et al. Frequent activation of EGFR in advanced chordomas. Clin Sarcoma Res. 2011;1(1):4. [PubMed]
8.
Shalaby A, Presneau N, Ye H, et al. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target. J Pathol. 2011;223(3):336-346. [PubMed]
9.
Presneau N, Shalaby A, Idowu B, et al. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br J Cancer. 2009;100(9):1406-1414. [PubMed]
10.
Shalaby AA. Molecular Analysis of Chordomas and Identification of Therapeutic Targets. PhD Dissertation, University College London. http://discovery.ucl.ac.uk/20213/1/20213.pdf. Published June 2010.
11.
Lee-Jones L, Aligianis I, Davies P, et al. Sacrococcygeal chordomas in patients with tuberous sclerosis complex show somatic loss of TSC1 or TSC2. Genes Chromosomes Cancer. 2004;41(1):80-85. [PubMed]
12.
McMaster M, Goldstein A, Parry D. Clinical Features Distinguish Childhood Chordoma Associated with Tuberous Sclerosis Complex (TSC) from Chordoma in the General Pediatric Population. J Med Genet. 2011;48(7):444-449. [PMC]
13.
Börgel J, Olschewski H, Reuter T, Miterski B, Epplen J. Does the tuberous sclerosis complex include clivus chordoma? A case report. Eur J Pediatr. 2001;160(2):138. [PubMed]
14.
Choy E, MacConaill L, Cote G, et al. Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1. PLoS One. 2014;9(7):e101283. [PubMed]
15.
Tauziéde-Espariat A, Bresson D, Polivka M, et al. Prognostic and Therapeutic Markers in Chordomas: A Study  of 287 Tumors. J Neuropathol Exp Neurol. 2016;75(2):111-120. [PubMed]
16.
Tarpey P, Behjati S, Young M, et al. The driver landscape of sporadic chordoma. Nat Commun. 2017;8:890. [PMC]
17.
Fasig J, Dupont W, LaFleur B, Olson S, Cates J. Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma. Neuropathol Appl Neurobiol. 2008;34(1):95-104. [PubMed]
18.
Dobashi Y, Suzuki S, Sato E, Hamada Y, Yanagawa T, Ooi A. EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol. 2009;22(10):1328-1340. [PubMed]
19.
de C, Guimaraes G, Aguiar S, et al. Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome. Hum Pathol. 2013;44(9):1747-1755. [PubMed]
20.
Chen H, Zhang K, Wu G, Song D, Chen K, Yang H. Low expression of PHLPP1 in sacral chordoma and its association with poor prognosis. Int J Clin Exp Pathol. 2015;8(11):14741-14748. [PubMed]
21.
Bosotti R, Magnaghi P, Di B, et al. Establishment and genomic characterization of the new chordoma cell line Chor-IN-1. Sci Rep. 2017;7(1):9226. [PubMed]
22.
Magnaghi P, Salom B, Cozzi L, et al. Afatinib is a new therapeutic approach in chordoma with a unique ability to target EGFR and Brachyury. Mol Cancer Ther. December 2017. [PubMed]
23.
Wu Z, Wang L, Guo Z, et al. Experimental study on differences in clivus chordoma bone invasion: an iTRAQ-based quantitative proteomic analysis. PLoS One. 2015;10(3):e0119523. [PubMed]
24.
Chen K, Mo J, Zhou M, et al. Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis. Med Oncol. 2014;31(4):886. [PubMed]
25.
Han S, Polizzano C, Nielsen G, Hornicek F, Rosenberg A, Ramesh V. Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas. Clin Cancer Res. 2009;15(6):1940-1946. [PubMed]
26.
Liang W S, Millis S Z, Gatalica Z, Reddy S K, Little A, Van Tine B A. Identification of actionable targets in chordomas using a multiplatform molecular analysis, and response with targeted therapy [abstract]. 2015 ASCO Annual Meeting. http://meetinglibrary.asco.org/record/111630/abstract. Published 2015.
27.
Scheipl S, Barnard M, Cottone L, et al. EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. J Pathol. 2016;239(3):320-334. [PubMed]
28.
Alholle A, Brini A, Bauer J, et al. Genome-wide DNA methylation profiling of recurrent and non-recurrent chordomas. Epigenetics. 2015;10(3):213-220. [PubMed]
29.
Otani R, Mukasa A, Shin M, et al. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma. J Neurosurg. July 2017:1-10. [PubMed]
30.
Ricci-Vitiani L, Runci D, D’Alessandris Q, et al. Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin. Neoplasia. 2013;15(7):773-782. [PubMed]
31.
Lee D, Zhang Y, Kassam A, et al. Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma. PLoS One. 2015;10(8):e0134426. [PMC]
32.
Zohreh J, Alexander S, Ines A, et al. Influence of Silibinin and  β – β -Dimethylacrylshikonin on Chordoma Cells. P. June 2018. doi:10.1016/j.phymed.2018.06.005
33.
Davies J, Robinson A, Cowdrey C, et al. Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma. J Neurosurg. 2014;120(2):331-336. [PubMed]
34.
Burger A, Vasilyev A, Tomar R, et al. A zebrafish model of chordoma initiated by notochord-driven expression of HRASV12. Dis Model Mech. 2014;7(7):907-913. [PubMed]
35.
Chay W, Teo M, Sittampalam K, Toh H. Effective use of thalidomide in the treatment of recurrent metastatic chordoma. J Clin Oncol. 2011;29(16):e477-80. [PubMed]
36.
Stacchiotti S, Marrari A, Tamborini E, et al. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol. 2009;20(11):1886-1894. [PubMed]
37.
Trapani D, Conforti F, De P. EGFR Inhibition in a Pretreated Sacral Chordoma: A Role for Erlotinib? Case Report and a Brief Review of Literature. Transl Med UniSa. 2017;16:30-33. [PMC]
38.
Lebellec L, Chauffert B, Blay J, et al. Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d’Expression Française (ANOCEF). Eur J Cancer. 2017;79:119-128. [PubMed]
39.
Stacchiotti S, Morosi C, Lo V, et al. Imatinib and Everolimus in Patients With Progressing Advanced Chordoma: A Phase 2 Clinical Study. Cancer. September 2018. [PubMed]